AYTU
Aytu BioPharma's Fiscal 2026 Fourth Quarter Results Reveal Promising Growth Potential for EXXUA and ADHD Business
A recent conference call by Aytu BioPharma provided insight into the company's fiscal 2026 fourth quarter results, showcasing promising growth potential for its flagship product, EXXUA, and its ADHD business. Josh Disbrow, Chief Executive Officer of Aytu BioPharma, expressed his excitement about the progress made and the opportunity